Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)
Key facts
- Who runs it
- Yanqing Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 288 people, planned
- Started
- 1 Mar 2025
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Pinaverium bromide
- Placebo for control group
- Record updated
- 20 April 2025
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Gender is not limited, age range is 18-85 years old (inclusive)
- Perform P-ESWL treatment for painful chronic pancreatitis with positive pancreatic duct stones ≥ 5mm, mainly located in the head or body of the pancreas
Who cannot take part
- Acute pancreatitis within 3 days prior to ESWL
- Chronic pinaverium bromide use with <3-day washout period
- Severe cardiac/pulmonary dysfunction precluding anesthesia tolerance
- Advanced liver disease (e.g., liver failure, cirrhosis, ascites, abscess)
- Suspected or confirmed pancreatic malignancy
- Known allergy to pinaverium bromide
- Requiring repeat ESWL during the study period
- Anticoagulant use within 3 days or coagulopathy
- Arteriosclerosis or aortic aneurysm along shockwave transmission path
- Pregnancy or lactation
- Declined participation
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate whether perioperative pinaverium bromide (a calcium antagonist) reduces post-ESWL complications (pancreatitis, abdominal pain, infection) in chronic pancreatitis patients with pancreatic duct stones ≥5mm. A single-center, randomized, double-blind, placebo-controlled design will be used, with 288 participants allocated to either pinaverium bromide (100mg tid) or placebo before and after p-ESWL.
The 2 groups in the trial
- Pinaverium BromideTreatment being tested
Preoperative, intraoperative, and postoperative oral administration of 100mg tid of povidone bromide in p-ESWL
- PlaceboPlacebo, for comparison
Preoperative, intraoperative, and postoperative oral administration of 100mg tid of placebo in p-ESWL
Treatment: Placebo for control group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP): a Single-center, Double-blind, Randomized, Placebo-controlled Trial.
- Criteria questions
- Built from NCT06936800, who can take part
- Record updated
- 20 April 2025